2603.00203 Optimizing Multi-Drug TB Treatment Regimens: Pharmacokinetic-Pharmacodynamic Modeling of Combination Therapy
Tuberculosis remains a leading infectious disease cause of mortality, with rising drug-resistant strains creating urgent need for optimized treatment regimens. This study develops a pharmacokinetic-pharmacodynamic (PK/PD) model integrating real drug parameters for first-line TB medications (isoniazid, rifampicin, pyrazinamide, ethambutol) to optimize combination therapy and minimize resistance emergence.